Funding for this research was provided by:
prostate cancer uk
Received: 13 July 2021
Accepted: 4 August 2021
First Online: 18 August 2021
: Ethics committee approval has been granted by South London Research Ethics Committee (REC reference 19/LO/0712), and the trial is registered with ExternalRef removed identifier NCT04049747. The first site opened on 11 December 2019.
: Not applicable.
: HA’s research is supported by core funding from the United Kingdom’s National Institute of Health Research (NIHR) Imperial Biomedical Research Centre. HA currently receives funding from the Wellcome Trust, Medical Research Council (UK), Cancer Research UK, Prostate Cancer UK, The Urology Foundation, BMA Foundation, Imperial Health Charity, NIHR Imperial BRC, Sonacare Inc., Trod Medical and Sophiris Biocorp for trials in prostate cancer. HA is a paid medical consultant for Sophiris Biocorp and Sonacare Inc. HA is a proctor for cryotherapy and HIFU and paid for training other surgeons in these procedures. HA is paid proctor for Rezum for the treatment of benign prostate hyperplasia.MW receives a travel grant and a loan of device from Zicom Biobot.TTS receives funding from Prostate Cancer UK and the St Peters Trust for clinical research and has received funding for conference attendance from Astellas, Ferring and Galil Medical.DR is funded by a research grant from Prostate Cancer UK, grant number RIA17-ST2-012. She has received funds to travel/attend conference from Imperial Healthcare Charity and Sonacare.TD has a private practice which includes focal therapy with HIFU and Cryotherapy and is associated with The Focal Therapy Clinic, which markets focal therapy and sends me patients to advise. TD has no stocks or appointments from device manufacturers. TD has previously received honoraria for teaching from manufacturers of focal therapy devices from Sonacare and Boston scientific.MRS reports grants and non-financial support outside the submitted work from Astellas, grants from Clovis Oncology, grants and non-financial support from Janssen, grants and non-financial support from Novartis, grants and non-financial support from Pfizer, grants and non-financial support from Sanofi and personal fees from Lilly Oncology and personal fees from Janssen all outside the submitted work.